Natixis Advisors LLC Has $94.32 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Natixis Advisors LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 292,724 shares of the medical research company’s stock after buying an additional 15,092 shares during the quarter. Natixis Advisors LLC owned approximately 0.05% of Amgen worth $94,319,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Mizuho Securities USA LLC boosted its holdings in shares of Amgen by 88.8% during the 3rd quarter. Mizuho Securities USA LLC now owns 78,092 shares of the medical research company’s stock worth $25,162,000 after buying an additional 36,733 shares during the period. Northcape Wealth Management LLC grew its position in shares of Amgen by 187.2% in the third quarter. Northcape Wealth Management LLC now owns 8,840 shares of the medical research company’s stock valued at $2,848,000 after purchasing an additional 5,762 shares during the last quarter. Gouws Capital LLC grew its position in shares of Amgen by 2.5% in the third quarter. Gouws Capital LLC now owns 16,663 shares of the medical research company’s stock valued at $5,369,000 after purchasing an additional 400 shares during the last quarter. Birchcreek Wealth Management LLC lifted its holdings in Amgen by 6.8% during the 3rd quarter. Birchcreek Wealth Management LLC now owns 899 shares of the medical research company’s stock worth $290,000 after purchasing an additional 57 shares during the last quarter. Finally, Empirical Finance LLC boosted its stake in Amgen by 2.1% in the 3rd quarter. Empirical Finance LLC now owns 18,754 shares of the medical research company’s stock valued at $6,043,000 after purchasing an additional 380 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on AMGN shares. Barclays boosted their target price on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, UBS Group lowered their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Stock Performance

Shares of AMGN stock opened at $283.61 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a 50-day moving average of $320.85 and a 200-day moving average of $318.36. Amgen Inc. has a one year low of $260.52 and a one year high of $346.85. The company has a market cap of $152.45 billion, a P/E ratio of 36.31, a P/E/G ratio of 2.69 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter last year, the business posted $4.96 EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.